TCGA-77-A5G6-01A-11R-A27Q-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 66
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.560
- E2F_TARGETS+0.550
- MYC_TARGETS_V1+0.470
- MITOTIC_SPINDLE+0.400
- MYC_TARGETS_V2+0.370
- WNT_BETA_CATENIN_SIGNALING+0.370
- DNA_REPAIR+0.310
- SPERMATOGENESIS+0.140
- PROTEIN_SECRETION+0.120
- OXIDATIVE_PHOSPHORYLATION+0.090
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.620
- INTERFERON_GAMMA_RESPONSE-0.600
- INFLAMMATORY_RESPONSE-0.530
- ALLOGRAFT_REJECTION-0.520
- IL6_JAK_STAT3_SIGNALING-0.500
- COMPLEMENT-0.470
- COAGULATION-0.450
- IL2_STAT5_SIGNALING-0.410
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.400
- TNFA_SIGNALING_VIA_NFKB-0.390
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-33-4587-01A-11R-2125-07 | — | cohortMD1 | 0.944 |
| 2 | BS_N6N147BY | Embryonal tumors | — | 0.927 |
| 3 | BS_K25F4J3V | ATRT | — | 0.925 |
| 4 | TCGA-O2-A5IB-01A-11R-A27Q-07 | — | cohortMD1 | 0.925 |
| 5 | SRR8518295 | — | E | 0.923 |
| 6 | SRR8613725 | — | E | 0.923 |
| 7 | TCGA-NC-A5HH-01A-11R-A26W-07 | — | cohortMD1 | 0.922 |
| 8 | SRR13780247 | — | cohortMD1 | 0.922 |
| 9 | TCGA-66-2793-01A-01R-1201-07 | — | cohortMD1 | 0.922 |
| 10 | SRR12696755 | — | — | 0.921 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.560 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.470 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.400 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.370 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.370 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.140 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.120 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.090 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.080 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.040 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.010 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.010 | Inavolisib | — uncovered |